within Pharmacolibrary.Drugs.ATC.B;

model B02AB05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.10166666666666666,
    adminDuration  = 600,
    adminMass      = 300.0,
    adminCount     = 1,
    Vd             = 0.017,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Ulinastatin is a broad-spectrum protease inhibitor, also known as urinary trypsin inhibitor. It is mainly used as an anti-inflammatory and organ-protective agent, particularly in the management of acute pancreatitis and sepsis. Ulinastatin is approved and used in several countries (notably Japan, China, India) for the treatment of acute inflammatory conditions and shock.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following a single intravenous dose in healthy adult volunteers (age: 18-40), both sexes.</p><h4>References</h4><ol><li><p>Jönsson-Berling, BM, &amp; Ohlsson, K (1991). Distribution and elimination of intravenously injected urinary trypsin inhibitor. <i>Scandinavian journal of clinical and laboratory investigation</i> 51(6) 549–557. DOI:<a href=&quot;https://doi.org/10.3109/00365519109104564&quot;>10.3109/00365519109104564</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1767247/&quot;>https://pubmed.ncbi.nlm.nih.gov/1767247</a></p></li><li><p>Matsukawa, H, et al., &amp; Shiraga, N (1998). [Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis--clinical effect of arterial injection of ulinastatin]. <i>Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology</i> 95(11) 1229–1234. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9852726/&quot;>https://pubmed.ncbi.nlm.nih.gov/9852726</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B02AB05;
